BIO Business Development Fundamentals Course Faculty

  • Recommend
  • Tweet
  • Print
  • Email

2015 Business Development Fundamentals Course Faculty

This page shows the 2015 Business Development Fundamentals course faculty members. We also offer an Advanced Business Development course- click here to view the Advanced Business Development faculty.

Shruti Abbato
Principal, Perspicere, LLC

Shruti Abbato is a Principal at Perspicere LLC, an advisory business focused on providing transaction and strategy related support to life science companies. Prior to Perspicere, Ms. Abbato was Director of Business Development at Human Genome Sciences, Inc. (HGS), a public biopharmaceutical company, acquired by GlaxoSmithKline (GSK) in July 2012.

Ms. Abbato joined HGS in 2000 and was responsible for search and evaluation, in- and out-licensing transactions, and merger and acquisition activities for broadening HGS' pipeline of therapeutic products and portfolio of enabling antibody and protein technologies. She has a depth of experience in strategic, financial, and commercial assessments, and in negotiating term sheets and contracts for a broad range of transactions. She has led numerous transaction processes and established multiple partnerships for HGS with biopharmaceutical and pharmaceutical companies. In addition, Ms. Abbato was a member of the deal team for HGS' sale process (and subsequent acquisition by GSK) and was responsible for sale related due diligence activities. Following the acquisition of HGS and through February 2013, Ms. Abbato was co-founder of and responsible for venture financing activities for a spin-off of HGS’ research division.

Ms. Abbato started her career in life sciences in 1995 and was at Merck & Co. and then at North American Vaccine, Inc., until 1999, where she held process engineering roles of increasing responsibilities for the development and production of biologics. She has an M.B.A. from the University of Pittsburg's Katz School of Business with a concentration in Finance. She also holds Bachelor's degrees in Chemical Engineering and in Biochemistry from the University of Maryland at College Park.

Anjan Aralihalli
CBO, ActoGeniX, a division of Intrexon Corporation

Anjan Aralihalli joined ActoGenix as Chief Business Officer in September 2013.

Anjan has over 20 years of international biopharmaceutical experience in clinical trial management, sales, marketing, operations, strategic planning and business development. Prior to ActoGeniX, he worked at Shionogi Inc., where he led the $127 Million acquisition of Victory Pharma. Between 2002-2010, he worked at Sanofi (Aventis) in both Canada and the United States in business development and strategic planning. Prior to joining Aventis, he worked in sales and marketing at Abbott Canada.

Anjan holds an MBA from Queen’s University (Canada).

Frank J. Carillo
 Founder and Chairman, ECG, Inc.

Beyond Frank's overall management of the firm's pharmaceutical and healthcare specialty practice, he has worked with clients who must present new drug applications to FDA Advisory Committee Meetings for approval and commercial release. In doing so, ECG has achieved an impressive record of success. In the ever-changing and highly charged world of healthcare delivery and management, Frank and his partners consult and coach CEOs and senior executives of pharmaceutical companies, health care providers, experts from academia, legislators and consulting firms on strategies that address this volatile national issue.

In that capacity, Frank has been instrumental in the success of multiple FDA Advisory Committee presentations, generating a powerful record of approvals. Frank and ECG have an incomparable record of success in building the explanations and advocacy necessary for helping regulators and academicians see the benefits in new data while maintaining appropriate context around risk.

He has authored numerous articles for business and professional journals and has been featured on various national media outlets including CNN, Bloomberg, CNBC, ABC News, and Fox News. Frank is also a prominent community leader. This role extends to his work with spokespeople for several religious denominations.

Frank is a graduate of the University of Pennsylvania's Wharton School of Business and sits on the board of directors of several foundations and public companies.

Mark Cochran, PhD
Managing Director, Johns Hopkins Healthcare 

Mark A. Cochran, PhD, is the Managing Director of Johns Hopkins Healthcare Solutions, a commercialization unit within Johns Hopkins Medicine that expands and manages partnerships with the business world, fostering collaborations among faculty and clinicians to leverage their intellectual assets, and exploring opportunities to share Hopkins-based solutions with external markets. Dr. Cochran’s professional experience spans all levels of the drug discovery, development and healthcare value chain including operational and executive roles in academic, venture capital, pharmaceutical and biotechnology industries. His previous experience includes Bayer Pharmaceuticals, last serving as Vice President of Business Development, Biotechnology, in Berkeley, California; Project Director of Recombinant Factor VIII (Kogenate); and Head of Molecular Biology and Biochemistry in Wuppertal Germany. Dr. Cochran was the CEO and executive director of the Blanchette Rockefeller Neurosciences Institute, which targets advanced research of memory and memory disorders, particularly Alzheimer’s disease. Dr. Cochran’s experience in venture capital includes MDS Capital Corp. and NeuroVentures Capital, as senior managing director. NeuroVentures was a fund specializing in the neurosciences and invested in companies developing drugs, devices and other medical technologies for clinical neuroscience. Dr. Cochran holds a doctorate in microbiology and immunology from Queen’s University, Kingston, Ontario; a master’s in microbiology from the University of Guelph, Ontario, and a bachelor’s degree from the University of Toronto. After he completed a postdoctoral fellowship at the National Institutes of Health, Dr. Cochran co-founded MicroGeneSys, Inc., a Connecticut-based vaccine company (now called Protein Sciences). 

Christine T. Fischette, PhD
CEO, BioLinkUp, LLC

Christine T. Fischette is CEO BioLinkUp, LLC, a Corporate Strategy/Business Development Consulting entity, Senior Advisor at Griffin Securities, Inc., NY, a boutique investment banking firm, and Board member of GCA Therapeutics, a US-based conduit which seeks to in-license Western technology, pharmaceuticals and devices for the China market. She serves on private company Business/Scientific Advisory Boards for therapeutics/devices, is Chair of the M&A Committee for the Licensing Executive Society (LES), Co-Chair for the LES NYC Chapter, an invited reviewer of grant proposals at Rockefeller University to assess future development/commercialization potential, and frequently speaks on BioPharma panels at local/international meetings.

Formerly, she was President of Enzo Therapeutics, Inc., a division of Enzo Biochem (ENZ:NYSE), and has spent 25+ years in Roche, Novartis and Pfizer with increasing areas of responsibility in operational and strategic roles covering multiple therapeutic areas of drug development, commercialization and business development. She functioned as Head of Negotiation, Global Business Development & Licensing for various therapeutic Business Franchise Boards at Novartis Pharmaceuticals where she identified, negotiated and executed multiple deals involving various deal structures, including acquisitions, with US, European, Japanese and Indian companies. She held various positions of increasing responsibility at Pfizer, NY directing preclinical/clinical development, IND’s/NDA’s, medical marketing, marketing and business development. During her tenure at Pfizer she directed the entire drug development process and subsequent marketing effort for an anti-diabetes therapy, Glucotrol XL®, and became head of Pfizer’s US commercial diabetes division. 

Richard Hoffman
Partner, WilmerHale

Mr. Hoffman is a seasoned lawyer, consultant and entrepreneur in the life sciences industry, and has significant experience in establishing new companies, negotiating and closing venture capital financings, in-licensing technologies, and developing and implementing corporate and business development strategies. Mr. Hoffman also has a successful track record in structuring, negotiating, and documenting strategic deals with both public and private companies.

From 1998 until 2013, Mr. Hoffman dedicated himself to pursuing entrepreneurial endeavors, serving as a legal advisor and business consultant to numerous biotech companies. Most recently, Mr. Hoffman was principal at R.A. Hoffman Consulting, which provided entrepreneurs and early-stage biotechnology, medical device and health care information companies with advice on corporate and business development strategies and tactics.

Mr. Hoffman began his career as an associate and, later, as junior partner at Hale and Dorr LLP. He worked in the corporate group from 1987 through 1994, representing biotechnology and medical device companies in public offerings, collaborative research arrangements, strategic alliances, intellectual property licensing and venture capital financings. In 1994, he became vice president of Finance and Business Development at Hybridon, Inc. (now a public company, Idera Pharmaceuticals) and later served in a similar role at biotech company Avitech, Inc.

Jeff Karan
Managing Partner, Mavericks Capital

Jeff brings over 30 years of investment banking and corporate advisory experience to Mavericks Capital. He started his career in 1980 at Morgan Stanley and subsequently moved to Goldman Sachs, each in their NY offices. Jeff had over $5B in cumulative transaction experience before starting his own investment bank in Silicon Valley. In addition to extensive knowledge of capital raising and merger & acquisitions, Jeff has advised clients on corporate strategy, business valuation, and a wide range of strategic partnership structures, and speaks on investment banking topics in healthcare internationally.

Mavericks Capital is the healthcare spinout of Woodside Capital Partners, a boutique investment bank Jeff founded in 2001. He holds an MBA from Dartmouth’s Amos Tuck School of Business Administration (Tuck Scholar) and a BA in Economics from Dartmouth College.  He later received an MA in Comparative Philosophy and Religion on the west coast.  Jeff is an avid skier and cyclist and is passionate about philosophy, the history of ideas, poker theory, and global economic analysis. (FINRA 7, 24, 63, 79, 99)

Philippe Nore
CEO and Co-founder, MiNDERA Corp.

Philippe Nore is an experienced executive specialized in clinical diagnostics, genomics and life science tools. He currently is CEO and co-founder of MiNDERA, an early stage clinical diagnostics company. Before founding MiNDERA, Philippe Nore was Senior International Business Leader at Roche Diagnostics. He was responsible for the development and commercialization of the Ventana Digital Pathology products (hardware, software, algorithms to score assays) in the cancer diagnostics market, including global P&L responsibility. During his tenure at Roche he has successfully launched several FDA-approved products.

Prior to that, he was a Senior Engagement Manager at L.E.K. Consulting where he worked with CEOs of small and midsize biotech and life sciences companies. Earlier, he worked at Life Technologies where he headed Strategic Planning and Business Development for the DNA Sequencing business Unit and led the Next-Generation Sequencing taskforce. He also spent 7 years at Bain & Company where he consulted for Fortune 500 companies.

Philippe has negotiated numerous licensing and acquisition transactions in his career and has deep expertise in strategic and financial valuation of biotech assets.

Philippe holds a MSc. in chemistry from ESPCI (Paris) and an MBA from the Wharton School where he graduated as a Palmer Scholar.


Robert Silverman, JD, PhD
Senior Vice President and General Counsel, Concert Pharmaceuticals, Inc.

Robert Silverman, J.D., Ph.D. has served as Concert Pharma's Senior Vice President and General Counsel since December 2010 and prior to that was Convert Pharma's Vice President and General Counsel from January 2007 to December 2010. Prior to joining Concert, he served in various legal related roles at Millennium Pharmaceuticals, Inc., a pharmaceutical company, Vertex and FMC Corporation, a chemical manufacturing company. Dr. Silverman received his J.D. from Rutgers-Camden Law School, a Ph.D. in organic chemistry from the University of New Mexico and a B.A. from Lehigh University.

Patricia Sinatra
Senior Vice President, Business Development, Serina Therapeutics

Patricia Sinatra is SVP of Business Development at Serina Therapeutics where she is responsible for leading business development and alliance management activities for the company.  She joined Serina from Vector Strategic Advisors, a licensing and strategic marketing consulting firm where she worked with a variety of biopharma as well as academic clients.  Previously, she held VP roles in licensing and commercial strategy for Telomere Diagnostics and Sutro Biopharma. Prior to Sutro, she held business development, alliance management and marketing positions for Dynavax Technologies, Abgenix, Matrix Pharmaceutical and SEQUUS Pharmaceuticals (ALZA).

Earlier in her career, Ms. Sinatra also served as a regional marketing representative for hospital based products for SmithKline Beecham and was VP of Account Services for FCB Healthcare (formerly VICOM/FCB), a medical communications company.   organizes continuing education courses through the Biotechnology Industry Organization in business development and has participated in career development initiatives at the Gladstone Institutes in San Francisco.  She received her undergraduate degree in biology from SUNY and conducted post-graduate doctoral studies in microbiology at the University of Texas Southwestern Medical in Dallas, TX.   


Kenneth Weber, PhD
Partner, Kilpatrick Townsend & Stockton LLP

Kenneth Weber, PhD, focuses his practice on patent prosecution, particularly in the areas of molecular genetics, chemistry, pharmaceuticals, plant science, medical devices and microbial genetics. He regularly assists clients in patent portfolio management, due diligence reviews, validity/infringement opinions and licensing.

Dr. Weber's clients include public and private corporations across the United States. Representative corporate clients include Aqua Bounty Technologies; Avanir, Inc.; Biosensors International; and Corcept Therapeutics, Cepheid, Inc., Ciphergen Biosystems, Inc. and Sutro Biopharma based in California. Ken is a member of the American Bar Association and the American Intellectual Property Law Association. He received his J.D. degree from the University of Washington and holds a PhD in Plant Pathology.

Michael W. Young
Vice President, PAREXEL Clinical Research Services

Michael joined PAREXEL International in late 2014. He is an accomplished, pharmaceutical and biotech executive with award-winning marketing and commercial operations credentials. He is a sought-after subject matter expert in the discipline of Alliance Management where he has honed his skills as a collaboration manager in a broad spectrum of B2B strategic partnerships and with the Association of Strategic Alliance Professionals (ASAP). He excels in building high-performance teams which extract value from collaboration initiatives, deliver on global commercial launches, and exceed partner expectations.
Prior to joining PAREXEL International, he was Vice President; Alliance Management for a different global contract research organization (CRO) His dedicated team was globally-based and oversaw top tier clients engaged in clinical development alliances. During his 4 year tenure, he also innovated and built an external vendor alliance capability for the CRO to dramatically improve client interface and results.
Michael previously pioneered a global Alliance Marketing & Management department and capability for Eisai Inc. His group managed 70 strategic B2B alliances encompassing almost $4 Billion in revenue in 27 countries. Prior to this he spent eleven years as Director of Marketing and then Executive Director, Strategic Marketing, Ligand Pharmaceuticals Inc., which was acquired by Eisai in late 2006. He was responsible for the launch of Ligand’s six product oncology and supportive care portfolio. He also managed Ligand’s international marketing activities with the company’s licensees in Europe, Latin America, and Canada. His commercial career also includes sales management, marketing, and new product development positions at GSK, Adria Laboratories, and Bayer.
Among his credentials, Michael was named Medical Marketer of the Year by the Medical Marketing Association and in 2003 served as President of the national organization. He has been an active industry speaker and author and has presented at numerous conferences including BIO, the Association of Strategic Alliance Professionals, the American Association of Pharmaceutical Sciences, the Chinese American Pharmaceutical Association, and the Drug Information Association. Michael serves on the board of directors of the Cutaneous Lymphoma Foundation and advises several other patient advocacy groups. Michael received his undergraduate degree from Kenyon College and did his graduate work at The Ohio State University.


*As of 4/22/15 - BIO reserves the right to change topics, faculty and times.